

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.8889 - TEVA / PART OF P&G OTC

SECTION 1.2

Description of the concentration

1. On 25 May 2018, the Commission received notification of a proposed concentration pursuant to Article 3(1)(b) of Council Regulation (EC) 139/2004 involving the acquisition of sole control of part of the OTC business of PGT, which is a company solely controlled by P&G and in which Teva Pharmaceutical Industries Ltd ("**Teva**") has a minority stake ("**Target Business**").
2. The primary business activities of the undertakings concerned are:
 - Teva is an international pharmaceutical company headquartered in Israel and specialized in the development, production and marketing of generic and proprietary pharmaceutical products as well as biopharmaceuticals and active pharmaceutical ingredients; and
 - the Target Business is comprised of part of the OTC business of PGT.